Rhapsido Mechanism of Action, Dosing & Safety | FDA Label

Rhapsido (remibrutinib) in one screen Rhapsido is an oral Bruton’s tyrosine kinase (BTK) inhibitor approved by the US FDA on 30 September 2025 for chronic spontaneous urticaria (CSU) in adults who stay symptomatic on H1 antihistamines. It is the first…









